Sensus Healthcare, Inc. (SRTS) Announces Exclusive US Distribution Agreement with Mattioli for TransDermal Infusion System

December 1, 2021 8:32 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the signing of an exclusive U.S. distribution agreement with Mattioli Eng. Italia S.P.A. for its TransDermal Infusion System non-invasive drug delivery system. Sensus plans to begin marketing this System to dermatologists nationwide beginning immediately.

The TransDermal Infusion System is cleared by the U.S. Food and Drug Administration (FDA) for the local administration of ionic drug solutions into the body for medical purposes, and can be used as an alternative to injections. Sensus’ sales organization will market the system to dermatologists for skin rejuvenation treatments, pre-laser treatments, pre- and post-plastic surgery and other applications. In addition, Sensus plans to make rental programs and leasing facilities available, similar to current programs for its superficial radiation therapy and aesthetic lasers.

The System allows drugs to penetrate the skin’s innermost, hypodermic layer by increasing permeability. Faster than traditional iontophoresis, the TransDermal Infusion System allows delivery of drugs that are otherwise not able to be absorbed including Botox®, hyaluronic acid, lidocaine, collagen and others typically used in aesthetic procedures.

“We are delighted to collaborate with such a globally recognized and highly respected firm as Mattioli Eng. Italia,” said Joe Sardano, chairman and CEO of Sensus Healthcare. “Their device, which we intend to trademark as ‘TransDermal Infusion’ under the Sensus brand, is FDA-cleared for use on any part of the body currently treated with needle injections. This permits various fillers and other injectables to be administered without pain and without patient downtime. We believe this needle-free treatment will be embraced by aesthetic dermatology clinics as a competitive advantage and an advance in patient care.”

Commenting on the agreement, Gian Franco Bernabei, CEO of Mattioli Eng. Italia S.P.A., said, “I am very excited to begin this new collaboration with Sensus. They have a tremendous commercial network, compelling products and, most importantly, exceptional respect among the dermatology community. We look forward to a productive relationship as the Sensus team brings our technology to dermatologists across the U.S.”

Mark S. Nestor, M.D., Ph.D., Director of the Center for Clinical and Cosmetic Research™ and the Center for Cosmetic Enhancement® in Aventura, Florida, and the current President of the American Cutaneous Oncology Society, said, “The clinical and aesthetic dermatology community is excited for the potential of the newest innovative device from Sensus Healthcare. The ‘Transdermal Infusion’ system has been shown to be very effective at transferring topically applied medications, botulinum toxins and hyaluronic acid fillers (HA) into the skin without the need for any cutaneous disruption. Our pilot study presented at the Fall Clinical Dermatology Conference1 showed over an 80% reduction in sweat 30 days after a single topical infusion of 50 units of onabotulinum toxin in the axilla. Additional studies have shown significant cosmetic improvement with topically applied HA. We also look forward to future applications for both clinical and aesthetic Dermatology.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Related Entities